Steven Sugarman

1.9k citations

20 papers · 1.2k indexed · h-index 14

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Complementary and alternative medicine top 5%
- Acupuncture Treatment Research Studies

Papers in

Toxicology 2
- Bioactive Compounds and Antitumor Agents 2
Oncology 13
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 8
- Peptidase Inhibition and Analysis 4

Co-authors: Clifford A. Hudis Gabriella D’Andrea Larry Norton Michael L. Pearl Shinya Shibutani Naomi Suzuki Arthur P. Grollman Isamu Terashima
Journals: Journal of Clinical Oncology (7 papers)Clinical Cancer Research (2 papers)Clinical Breast Cancer (2 papers)Breast Cancer Research and Treatment (2 papers)Carcinogenesis (2 papers)
Partner nations: United States New Zealand Canada

In The Last Decade

Steven Sugarman

20 papers receiving 1.2k citations

Peers

Countries citing papers authored by Steven Sugarman

Since Specialization

Citations

This map shows the geographic impact of Steven Sugarman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Sugarman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Sugarman more than expected).

Fields of papers citing papers by Steven Sugarman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Sugarman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Sugarman. The network helps show where Steven Sugarman may publish in the future.

Co-authors

The 25 scholars most cited alongside Steven Sugarman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Sugarman Line = papers co-authored together Steven Sugarman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance) Breast Cancer Research and Treatment ·Shirley M. Bluethmann, Catherine M. Alfano, Jonathan D. Clapp, George Luta, Brent J. Small, Arti Hurria, Harvey Jay Cohen, Steven Sugarman, Hyman B. Muss, Claudine Isaacs, Jeanne S. Mandelblatt	2017	14
2	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience The Oncologist ·Jasmeet Singh, Anita Mamtani, Andrea V. Barrio, Monica Morrow, Steven Sugarman, Lee W. Jones, Anthony F. Yu, А А Даниленко, M. I. Lischkevitsch, Shanu Modi, 劉心宇, McDiarmid, Sujata Patil, Larry Norton, José Baselga, Clifford A. Hudis, Chau T. Dang	2017	27
3	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer Clinical Breast Cancer ·Neil M. Iyengar, Monica Fornier, Steven Sugarman, Maria Theodoulou, Tiffany A. Troso-Sandoval, Gabriella D’Andrea, Pamela Drullinsky, Devika Gajria, Shari Goldfarb, Elizabeth Comen, Diana Lake, Shanu Modi, Tiffany A. Traina, Mario E. Lacouture, Marcel J. Mélançon, Sujata Patil, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	2015	2
4	Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. Journal of Clinical Oncology ·Lillian M. Smyth, Neil M. Iyengar, Sarat Chandarlapaty, Steven Sugarman, Elizabeth Comen, Pamela Drullinsky, Nancy T. Sklarin, Tiffany A. Traina, Tiffany A. Troso-Sandoval, Sujata Patil, X. L. Wang, А А Даниленко, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	2015	1
5	Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology ·Neil M. Iyengar, Monica Fornier, Steven Sugarman, Maria Theodoulou, Tiffany A. Troso-Sandoval, Gabriella D’Andrea, Pamela Drullinsky, Mikio Ichihashi, Devika Gajria, Shari Goldfarb, Elizabeth Comen, Diana Lake, Shanu Modi, Tiffany A. Traina, Monta Feldmane, Sujata Patil, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	2014	1
6	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Clinical Cancer Research ·Shanu Modi, Alison Stopeck, Hannah Linden, David B. Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D’Andrea, Maura N. Dickler, Mary Ellen Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, Clifford A. Hudis	2011	328
7	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib Clinical Cancer Research ·Patrick G. Morris, Carol Chen, Richard M. Steingart, Martin Fleisher, Nancy U. Lin, Beverly Moy, Steven E. Come, Steven Sugarman, A. Abbruzzi, Gajanan P Arsalwad, Sujata Patil, Maura N. Dickler, Heather L. McArthur, Eric P. Winer, Larry Norton, Clifford A. Hudis, Chau T. Dang	2011	101
8	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea Journal of Clinical Oncology ·Chau T. Dang, Nancy U. Lin, Beverly Moy, Steven E. Come, Steven Sugarman, Patrick G. Morris, A. Abbruzzi, Carol Chen, Richard M. Steingart, Sujata Patil, Larry Norton, Eric P. Winer, Clifford A. Hudis	2010	36
9	Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer Clinical Breast Cancer ·Pamela Drullinsky, Steven Sugarman, Monica Fornier, Gabriella D’Andrea, Teresa Gilewski, Diana Lake, Tiffany A. Traina, X. L. Wang, Nancy T. Sklarin, Deena Atieh-Graham, Nancy Mills, Tiffany A. Troso-Sandoval, Andrew D. Seidman, Mohamed Babu, Jacqueline Issa, Sujata Patil, Larry Norton, Clifford A. Hudis	2010	4
10	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction Journal of Clinical Oncology ·Patrick G. Morris, Maura N. Dickler, Heather L. McArthur, Tiffany A. Traina, Steven Sugarman, Nancy U. Lin, Beverly Moy, Steven E. Come, Laura Godfrey, Nam-Hoon Kim, Carol Chen, Richard M. Steingart, Hope S. Rugo, Larry Norton, Eric P. Winer, Clifford A. Hudis, Chau T. Dang	2009	22
11	A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma Breast Cancer Research and Treatment ·Steven Sugarman, Carolyn Wasserheit, Elizabeth Y. Jimenez, Maxim Kulikovskiy, Ronald P. Toby, Nadya Bozza-Splitt, Tiffany A. Troso-Sandoval, Gabriella D’Andrea, Pamela Drullinsky, Diana Lake, A V Strelkova, Nancy Mills, Mary Ellen Moynahan, Xuze Zhang, Katherine S. Panageas, Larry Norton, Clifford A. Hudis	2008	9
12	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer Journal of Clinical Oncology ·Chau T. Dang, Monica Fornier, Steven Sugarman, Tiffany A. Troso-Sandoval, Diana Lake, Gabriella D’Andrea, Andrew D. Seidman, Nancy T. Sklarin, Maura N. Dickler, Violante E. Currie, Theresa Gilewski, Mary Ellen Moynahan, Pamela Drullinsky, Mark E. Robson, P.W.S. Perera, Nancy Mills, Richard M. Steingart, Katherine S. Panageas, Larry Norton, Clifford A. Hudis	2008	44
13	Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients Journal of Clinical Oncology ·Gary Deng, Andrew J. Vickers, K. Simon Yeung, Gabriella D’Andrea, Han Xiao, Alexandra S. Heerdt, Steven Sugarman, Tiffany A. Troso-Sandoval, Andrew D. Seidman, Clifford A. Hudis, Barrie R. Cassileth	2007	129
14	Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen Carcinogenesis ·Shinya Shibutani, Anisetti Ravindernath, Naomi Suzuki, Isamu Terashima, Steven Sugarman, Arthur P. Grollman, Michael L. Pearl	2000	87
15	Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen Carcinogenesis ·Shinya Shibutani, Anisetti Ravindernath, Naomi Suzuki, Isamu Terashima, Steven Sugarman, Arthur P. Grollman, Michael L. Pearl	2000	73
16	Tamoxifen−DNA Adducts Detected in the Endometrium of Women Treated with Tamoxifen Chemical Research in Toxicology ·Shinya Shibutani, Naomi Suzuki, Isamu Terashima, Steven Sugarman, Arthur P. Grollman, Michael L. Pearl	1999	72
17	Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer Journal of Clinical Oncology ·Anthony W. Tolcher, Steven Sugarman, Karen A. Gelmon, Roger Cohen, Mansoor N. Saleh, Claudine Isaacs, Leslie Young, Diane Healey, Nicole Onetto, William J. Slichenmyer	1999	202
18	Role of adjuvant therapy in surgically resected colorectal carcinoma Gastroenterology ·Frank A. Sinicrope, Steven Sugarman	1995	19
19	Applications for Liposomes in Human Malignancy: Current Status and Future Directions Medical Entomology and Zoology ·Steven Sugarman, Román Pérez-Soler	1995	4
20	Liposomes in the treatment of malignancy: a clinical perspective Critical Reviews in Oncology/Hematology ·Steven Sugarman, Román Pérez-Soler	1992	27

About Steven Sugarman

Steven Sugarman is a scholar working on Toxicology, Oncology, Cancer Research, Pharmacology and Biomaterials, having authored 20 papers that have together received 1.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (7 papers), Peptidase Inhibition and Analysis (4 papers), Estrogen and related hormone effects (3 papers), Inflammatory mediators and NSAID effects (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Nanoparticle-Based Drug Delivery (2 papers). The work is most often cited by research in Oncology (544 citations), Complementary and alternative medicine (103 citations), Radiology, Nuclear Medicine and Imaging (247 citations), Cancer Research (152 citations) and Toxicology (31 citations). Steven Sugarman has collaborated with scholars based in United States, New Zealand and Canada. Frequent co-authors include Clifford A. Hudis, Gabriella D’Andrea, Larry Norton, Michael L. Pearl, Shinya Shibutani, Naomi Suzuki, Arthur P. Grollman, Isamu Terashima, Sujata Patil and Maura N. Dickler. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Clinical Breast Cancer, Breast Cancer Research and Treatment and Carcinogenesis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact